Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18933
Title: Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies.
Austin Authors: Christidis, Daniel;McGrath, Shannon ;Perera, Marlon ;Manning, Todd G ;Bolton, Damien M ;Lawrentschuk, Nathan
Affiliation: Young Urology Researchers Organization (YURO), Melbourne, Australia
Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Issue Date: Jun-2017
metadata.dc.date: 2017-07-19
Publication information: Prostate international 2017; 5(2): 41-46
Abstract: The prevalence of benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms increases with our ageing population. Treatment of BPH traditionally begins with medical therapy and surgical intervention is then considered for those whose symptoms progress despite treatment. Minimally invasive surgical therapies have been developed as an intermediary in the treatment of BPH with the aim of decreasing the invasiveness of interventions. These therapies also aim to reduce morbidity and dysfunction related to invasive surgical procedures. Multiple treatment options exist in this group including mechanical and thermo-ablative strategies. Emerging therapies utilizing differing technologies range from the established to the experimental. We review the current literature related to these minimally invasive therapies and the evidence of their effectiveness in treating BPH. The role of minimally invasive surgical therapies in the treatment of BPH is still yet to be strongly defined. Given the experimental nature of many of the modalities, further study is required prior to their recommendation as alternatives to invasive surgical therapy. More mature evidence is required for the analysis of durability of effect of these therapies to make robust conclusions of their effectiveness.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18933
DOI: 10.1016/j.prnil.2017.01.007
ORCID: 0000-0003-2951-3726
0000-0002-1138-6389
0000-0001-5609-3769
0000-0002-5145-6783
0000-0001-8553-5618
PubMed URL: 28593165
ISSN: 2287-8882
Type: Journal Article
Subjects: Aquablation
Benign prostatic hypertrophyprostatic artery embolization
Minimally invasive surgical therapies
Prostatic stenting
Appears in Collections:Journal articles

Show full item record

Page view(s)

2
checked on Nov 29, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.